ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Can Autoimmune Conditions be Reversed? Researchers Make a Surprising Discovery

Scientifically-designed fasting diet lowers risks for major diseases

How One Tiny Molecule Turned into One Huge Health Breakthrough

Acupuncture boosts effectiveness of standard medical care for chronic pain, depression

Research on Astaxanthin Demonstrates Significant Whole Body Benefits

Humans have three times more brown body fat

Nutrients Boost Stem Cell Function

B12 Proven Essential for Every Cell

Soy isoflavones may benefit breast cancer patients

Dietary prebiotics improve sleep, buffer impacts of stress, says study

 
Print Page
Email Article

Randomized, Placebo-controlled, Double-blind Trial of Valomaciclovir (VALM) for Infectious Mononucleosis (IM) – Source: Interscience Conference on Antimicrobial Agents & Chemotherapy, Sep 14, 2009

  [ 15 votes ]   [ Discuss This Article ]
By Henry H Balfour Jr., et al. • www.ProHealth.com • September 16, 2009


[Note: As described in a Los Angeles Times article, “Antiviral drug found to reduce severity of mono,” viral load was reduced in treated youngsters, who averaged a 50% symptom improvement in 7.6 days vs. 11.1 days for placebo. The next challenge: identify factors that may justify treatment – e.g., characteristics that appear linked to more severe illness, or to later development of illnesses such as ME/CFS.]

Background: Infectious mononucleosis (IM) causes substantial loss of productivity in teenagers and young adults. We conducted an investigator-initiated clinical trial of the guanosine nucleoside prodrug Valomaciclovir (VALM) for infectious mononucleosis under an investigator IND.

Methods: Subjects over the age of 15 with acute infectious mononucleosis were randomized to 21 days of VALM 4 g/day or placebo (PBO) and followed for 6 mo. Clinical, virologic, immunologic and pharmacologic observations were made during 10 visits.

Results:
21 subjects ages 16 to 24 yr (median age, 19.6 yr) enrolled a median of 6 days after onset of infectious mononucleosis confirmed due to primary Epstein-Barr virus (EBV) infection. 11 were assigned to VALM and 10 to PBO.

• VALM subjects had significantly faster clinical improvement than PBO recipients as documented by comparing the slopes of the plots of their physical exam/symptom scores from each visit during the treatment period (95% confidence intervals did not overlap; P<0.05).

• Severity of illness and SF12 scores improved faster in VALM subjects but rates were not statistically significant.

• VALM produced a significant decrease in median EBV load in the oral compartment vs PBO (oral cell pellet, P=0.03; oral supernatant, P=0.001, unpaired t test, 2-sided).

• The proportion of subjects who had at least a 2 log10 decrease in EBV load in the oral compartment was also significantly different (VALM 8/11; PBO 2/10; P=0.03, Fisher exact test, 2-sided).

• No differences were found in clearance of EBV DNAemia, CD8:CD4 ratios, CD8 lymphocytosis, or CD8 responses to lytic and latent EBV tetramers in the VALM vs PBO subjects.

• 9 of 11 VALM subjects had at least 1 plasma concentration of H2G, the parent compound of VALM, above the in vitro IC50 for EBV in subject-derived lymphoblastoid cells, which is 2.1 micromolar.

Conclusions:
This is the first demonstration of a clinical benefit and an in vivo antiviral effect of VALM in acute infectious mononucleosis due to primary EBV infection.

This study encourages additional investigation of the role of VALM in the management of diseases associated with EBV.

[ClinicalTrials.gov Trial: NCT00575185]

Source: Interscience Conference on Antimicrobial Agents & Chemotherapy, Sep 14, 2009, San Francisco. Presentation Number V-1256a; Session 146 – Herpes Viruses and Other Viral Infections in Immunocompromised Hosts. By Balfour HH, Vezina HE, Hogquist KA, Brundage RC, Anderson BJ, Odumade OA. University of Minnesota, Minneapolis, USA.





Post a Comment

Featured Products From the ProHealth Store
Mitochondria Ignite™ with NT Factor® Optimized Curcumin Longvida® Energy NADH™ 12.5mg

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium

Natural Remedies

Fight Inflammation and Promote Cognitive Health with High-OPC Grape Seed Fight Inflammation and Promote Cognitive Health with High-OPC Grape Seed
"It's Not Easy Being Green" - But It Is Healthy
Enhance Eyelashes Naturally Enhance Eyelashes Naturally
Quercetin: Natural Support for Allergy & Inflammation Relief and More Quercetin: Natural Support for Allergy & Inflammation Relief and More
Improve Cardiovascular and Metabolic Health with Omega-7 Improve Cardiovascular and Metabolic Health with Omega-7

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map